Baxter aims to divide and conquer

US drugmaker Baxter International is spinning off its biopharmaceuticals business to create two independent companies.

The biopharma unit will include Baxter’s existing plasma- and recombinant protein-based drugs for haemophilia, along with treatments for other blood-related conditions. The company stated that it will look to add to its pipeline of treatments and diagnostics for bleeding disorders through collaborations and acquisitions.

The remaining ‘medical products’ outfit includes Baxter’s dialysis equipment, as well as intravenous drug delivery systems, anaesthetics and surgical equipment. That business will aim to grow by increasing its geographical reach and streamlining costs.

Related Content

Baxter to pay $4bn for dialysis firm

6 December 2012 Business

news image

Gambro makes products for hemodialysis and continuous renal replacement therapy

10 years ago - Alain Baxter

1 May 2012 Flashback

news image

British Olympic skier Alain Baxter had his bronze medal taken away after a post-race drug test showed traces of methamphetami...

Most Commented

Chlorinated compounds form in tea and coffee

24 November 2015 Research

news image

Treated water reacts with organics to form disinfection byproducts

Brazilian mine disaster releases dangerous metals

21 November 2015 News and Analysis

news image

Irreversible negative human health and environmental effects could result from Brazilian mine’s dam collapse